These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 16133108)

  • 1. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
    Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
    Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
    Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
    Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens.
    Hsieh CL; Pang VF; Chen DS; Hwang LH
    Hum Gene Ther; 1997 Nov; 8(16):1843-54. PubMed ID: 9382951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
    Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
    J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA.
    Naka T; Iwahashi M; Nakamura M; Ojima T; Nakamori M; Ueda K; Katsuda M; Miyazawa M; Ishida K; Yamaue H
    Cancer Sci; 2008 Feb; 99(2):407-13. PubMed ID: 18271939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
    Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
    Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.
    Schmidt K; Zilio S; Schmollinger JC; Bronte V; Blankenstein T; Willimsky G
    Blood; 2013 Mar; 121(10):1740-8. PubMed ID: 23305737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
    Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
    Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
    Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
    Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.